Literature DB >> 17322105

Analyses of very early hemopoietic regeneration after bone marrow transplantation: comparison of intravenous and intrabone marrow routes.

Qing Li1, Hiroko Hisha, Ryoji Yasumizu, Tian-Xue Fan, Guo-Xiang Yang, Qiang Li, Yun-Ze Cui, Xiao-Li Wang, Chang-Ye Song, Satoshi Okazaki, Tomomi Mizokami, Wen-Hao Cui, Kequan Guo, Ming Li, Wei Feng, Junko Katou, Susumu Ikehara.   

Abstract

In bone marrow transplantation (BMT), bone marrow cells (BMCs) have traditionally been injected intravenously. However, remarkable advantages of BMT via the intra-bone-marrow (IBM) route (IBM-BMT) over the intravenous route (IV-BMT) have been recently documented by several laboratories. To clarify the mechanisms underlying these advantages, we analyzed the kinetics of hemopoietic regeneration after IBM-BMT or IV-BMT in normal strains of mice. At the site of the direct injection of BMCs, significantly higher numbers of donor-derived cells in total and of c-kit(+) cells were observed at 2 through 6 days after IBM-BMT. In parallel, significantly higher numbers of colony-forming units in spleen were obtained from the site of BMC injection. During this early period, higher accumulations of both hemopoietic cells and stromal cells were observed at the site of BMC injection by the IBM-BMT route. The production of chemotactic factors, which can promote the migration of a BM stromal cell line, was observed in BMCs obtained from irradiated mice as early as 4 hours after irradiation, and the production lasted for at least 4 days. In contrast, sera collected from the irradiated mice showed no chemotactic activity, indicating that donor BM stromal cells that entered systemic circulation cannot home effectively into recipient bone cavity. These results strongly suggest that the concomitant regeneration of microenvironmental and hemopoietic compartments in the marrow (direct interaction between them at the site of injection) contributes to the advantages of IBM-BMT over IV-BMT. Disclosure of potential conflicts of interest is found at the end of this article.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17322105     DOI: 10.1634/stemcells.2006-0354

Source DB:  PubMed          Journal:  Stem Cells        ISSN: 1066-5099            Impact factor:   6.277


  12 in total

1.  Preferential expansion of human umbilical cord blood-derived CD34-positive cells on major histocompatibility complex-matched amnion-derived mesenchymal stem cells.

Authors:  Tomomi Mizokami; Hiroko Hisha; Satoshi Okazaki; Takashi Takaki; Xiao-Li Wang; Chang-Ye Song; Qing Li; Junko Kato; Naoki Hosaka; Muneo Inaba; Hideharu Kanzaki; Susumu Ikehara
Journal:  Haematologica       Date:  2009-03-31       Impact factor: 9.941

2.  CD4+ T cell-depleted lymphocyte infusion impairs neither the recovery of recipient thymus nor the development of transplanted thymus.

Authors:  Ming Shi; Ming Li; Yunze Cui; Lin Liu; Yasushi Adachi; Susumu Ikehara
Journal:  J Immunol       Date:  2013-02-04       Impact factor: 5.422

3.  A phase I/II trial of intrabone marrow cord blood transplantation and comparison of the hematological recovery with the Japanese nationwide database.

Authors:  N Kurita; M Gosho; Y Yokoyama; T Kato; N Obara; M Sakata-Yanagimoto; Y Hasegawa; N Uchida; S Takahashi; Y Kouzai; Y Atsuta; M Kurata; T Ichinohe; S Chiba
Journal:  Bone Marrow Transplant       Date:  2017-01-09       Impact factor: 5.483

4.  Autologous implantation of BMP2-expressing dermal fibroblasts to improve bone mineral density and architecture in rabbit long bones.

Authors:  Akikazu Ishihara; Steve E Weisbrode; Alicia L Bertone
Journal:  J Orthop Res       Date:  2015-08-12       Impact factor: 3.494

5.  Combination of intra-bone marrow-bone marrow transplantation and subcutaneous donor splenocyte injection diminishes risk of graft-versus-host disease and enhances survival rate.

Authors:  Ming Shi; Yasushi Adachi; Yunze Cui; Ming Li; Zhexiong Lian; Yuming Zhang; Seiji Yanai; Chieko Shima; Yuichiro Imai; Susumu Ikehara
Journal:  Stem Cells Dev       Date:  2010-12-22       Impact factor: 3.272

6.  Direct bone marrow injection of human bone marrow-derived stromal cells into mouse femurs results in greater prostate cancer PC-3 cell proliferation, but not specifically proliferation within the injected femurs.

Authors:  Bianca Nowlan; Elizabeth D Williams; Michael Robert Doran
Journal:  BMC Cancer       Date:  2022-05-17       Impact factor: 4.638

7.  Noninvasive tracking of donor cell homing by near-infrared fluorescence imaging shortly after bone marrow transplantation.

Authors:  Takashi Ushiki; Shinae Kizaka-Kondoh; Eishi Ashihara; Shotaro Tanaka; Masayoshi Masuko; Hideyo Hirai; Shinya Kimura; Yoshifusa Aizawa; Taira Maekawa; Masahiro Hiraoka
Journal:  PLoS One       Date:  2010-06-14       Impact factor: 3.240

8.  Histological Architecture Underlying Brain-Immune Cell-Cell Interactions and the Cerebral Response to Systemic Inflammation.

Authors:  Atsuyoshi Shimada; Sanae Hasegawa-Ishii
Journal:  Front Immunol       Date:  2017-01-19       Impact factor: 7.561

9.  Capacity of the medullary cavity of tibia and femur for intra-bone marrow transplantation in mice.

Authors:  Dieter Fink; Ulrike Pfeiffenberger; Tina Bernthaler; Sophie Schober; Kerstin E Thonhauser; Thomas Rülicke
Journal:  PLoS One       Date:  2019-11-07       Impact factor: 3.240

10.  Direct bone marrow HSC transplantation enhances local engraftment at the expense of systemic engraftment in NSG mice.

Authors:  Kathryn Futrega; William B Lott; Michael R Doran
Journal:  Sci Rep       Date:  2016-04-11       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.